Westfield Capital Management Co. LP Acquires 277,033 Shares of Glaukos Corporation (NYSE:GKOS)

Westfield Capital Management Co. LP grew its holdings in shares of Glaukos Corporation (NYSE:GKOS - Free Report) by 34.3% in the first quarter, according to its most recent filing with the SEC. The firm owned 1,084,184 shares of the medical instruments supplier's stock after acquiring an additional 277,033 shares during the quarter. Westfield Capital Management Co. LP owned about 1.90% of Glaukos worth $106,705,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of GKOS. Bessemer Group Inc. increased its holdings in shares of Glaukos by 133.9% in the first quarter. Bessemer Group Inc. now owns 276 shares of the medical instruments supplier's stock valued at $27,000 after buying an additional 158 shares in the last quarter. Whipplewood Advisors LLC raised its position in shares of Glaukos by 3,957.1% during the first quarter. Whipplewood Advisors LLC now owns 284 shares of the medical instruments supplier's stock worth $28,000 after purchasing an additional 277 shares during the period. First Horizon Advisors Inc. lifted its holdings in shares of Glaukos by 72.9% during the first quarter. First Horizon Advisors Inc. now owns 377 shares of the medical instruments supplier's stock valued at $37,000 after purchasing an additional 159 shares during the last quarter. Versant Capital Management Inc boosted its position in shares of Glaukos by 583.9% in the 1st quarter. Versant Capital Management Inc now owns 383 shares of the medical instruments supplier's stock valued at $38,000 after purchasing an additional 327 shares during the period. Finally, CoreCap Advisors LLC increased its stake in Glaukos by 36.4% in the 4th quarter. CoreCap Advisors LLC now owns 750 shares of the medical instruments supplier's stock worth $112,000 after purchasing an additional 200 shares in the last quarter. Institutional investors own 99.04% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. Wells Fargo & Company upped their price objective on shares of Glaukos from $86.00 to $92.00 and gave the company an "equal weight" rating in a research note on Thursday, July 31st. Mizuho set a $130.00 target price on shares of Glaukos in a research note on Thursday, July 31st. Morgan Stanley dropped their price target on Glaukos from $110.00 to $72.00 and set an "underweight" rating on the stock in a research report on Tuesday, May 6th. William Blair upgraded Glaukos to a "strong-buy" rating in a research report on Thursday, July 31st. Finally, Piper Sandler dropped their target price on Glaukos from $180.00 to $165.00 and set an "overweight" rating on the stock in a report on Tuesday, April 15th. One analyst has rated the stock with a sell rating, two have given a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $127.42.

Glaukos Stock Performance

NYSE GKOS traded down $1.28 during midday trading on Thursday, hitting $87.21. The company had a trading volume of 691,923 shares, compared to its average volume of 963,152. Glaukos Corporation has a fifty-two week low of $77.10 and a fifty-two week high of $163.71. The company has a quick ratio of 4.69, a current ratio of 5.51 and a debt-to-equity ratio of 0.09. The stock has a market cap of $5.00 billion, a price-to-earnings ratio of -52.79 and a beta of 0.78. The firm has a fifty day simple moving average of $97.51 and a two-hundred day simple moving average of $107.13.

Glaukos (NYSE:GKOS - Get Free Report) last posted its quarterly earnings results on Wednesday, July 30th. The medical instruments supplier reported ($0.24) earnings per share for the quarter, topping analysts' consensus estimates of ($0.26) by $0.02. The firm had revenue of $124.12 million for the quarter, compared to the consensus estimate of $115.49 million. Glaukos had a negative net margin of 21.43% and a negative return on equity of 8.59%. The business's revenue was up 29.7% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.52) earnings per share. Equities analysts forecast that Glaukos Corporation will post -1.08 earnings per share for the current fiscal year.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.